EGFR and non-small cell lung carcinoma: EGFR mutations contributing to NSCLC usually occur in the tyrosine kinase domain of EGFR, which has been targeted as a therapeutic approach via the successful development of anti-EGFR tyrosine kinase inhibitors [29].